Sickle Cell Disease [1]

Novartis is pursuing a comprehensive approach to tackling sickle cell disease. We are developing innovative new medicines to treat it and are working to expand people’s access to diagnosis and treatment.

Sickle cell disease is a hereditary and life-threatening condition that causes ongoing vascular damage and repeated injury to blood vessels and organs. This lifelong illness often takes an extreme emotional, physical, and financial toll on patients and their families.

For over 40 years Novartis has been committed to understanding sickle cell disease and working towards treatment. Through research, educational resources and access programs, we will continue our efforts to support patients, healthcare providers and caregivers.
Screening a baby for sickle cell disease in Ghana

A pioneering collaboration brings sickle cell treatment to more people

A dedicated doctor, the government of Ghana and Novartis are working together to improve the diagnosis and treatment of sickle cell disease.

Watch the video to see the moving story of a young sickle cell patient named Caleb and learn about the collaborative effort to screen more newborn babies for the disease and improve people’s access to medicine and care.

Video of Sickle Cell Disease

Raising awareness with untold sickle cell stories

Sickle cell patients from around the world have shared their stories with us and are helping show what living with this disease truly looks like. They are not alone. We are a large community and support system and together we can do more.

Every day, people endure the painful and life-threatening symptoms of sickle cell disease in the shadows because of fear, stigma, and isolation. Now, a new picture is emerging.
Nana is a sickle cell patient from Ghana

Together with Dr. Alex Kumar, a global health physician and photographer, Novartis is sharing images and stories from around the globe that are intended to inspire the sickle cell community and raise awareness of the disease to help change how the world sees it.

Zakareya is a sickle cell patient from Bahrain

More needs to be done. That is why Novartis is working together with patient support groups around the world to help bring sickle cell disease out of the shadows. Learn more at UntoldSickleCellStories.com [2]
News

Partnership in Ghana

Read More
News

- Government of Ghana makes hydroxyurea available to people with sickle cell disease through the first of its kind public-private partnership with global medicines company Novartis [5]
- Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease [6]
- Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program [7]
- FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101) [8]

Novartis Social Business (NSB)

NSB supports global public health through novel sustainable business models. Our activities are rooted in local communities, where we work with partners to provide affordable, high-quality medicines against infectious and chronic diseases while strengthening healthcare capacity. Everything we do relies on our network of partners, who share our purpose.

Learn More [9]

Source URL: https://www.novartis.com/global-health/sickle-cell-disease

Links